BioGend Therapeutics Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was TWD 1.461 million. Operating loss was TWD 167.113 million compared to TWD 166.197 million a year ago. Net loss was TWD 162.903 million compared to TWD 167.456 million a year ago. Basic loss per share was TWD 2.01 compared to TWD 2.76 a year ago.